COVID-19 treatments



Paxlovid is an option for treating mild-to-moderate COVID-19 in adults and pediatric patients who are 12 years or older, weigh at least 88 pounds and are at high risk for progression to severe COVID-19.

The medication needs to be taken within five days of symptom onset. Pharmacists and physicians can prescribe Paxlovid. 

To get this medication, please connect with your primary care doctor. Nebraska Medicine patients can also submit an E-Visit.

If you do not have a primary care doctor, you can:

Outpatient treatments

Monoclonal antibody infusions after a positive COVID-19 test or confirmed COVID-19 exposure

Bamlanivimab with etesevimab, casirivimab with imdevimab, and sotrovimab are COVID-19 neutralizing antibody treatments for high risk patients who have tested positive for COVID-19, or who have been directly exposed to someone with COVID-19.

Antibody treatments are given to people who aren't in the hospital. They may help your body to better fight the virus, preventing a COVID-19 infection from progressing. 

Some things to note about these treatments:

  • Supplies are very limited. It will not be possible for everyone who becomes sick with COVID-19 to receive one of these treatments at this time
  • These treatments are NOT available at our emergency departments or clinics
  • If you meet the qualifications to receive one of these treatments, please ask your health care provider to submit you for consideration

Monoclonal antibody injection for immunocompromised people to prevent a COVID-19 infection 

For people who have a compromised immune system, or a severe allergy to the COVID-19 vaccines,  a COVID-19 neutralizing antibody treatment called tixagevimab with cilgavimab may be an option. 

We are working with our physicians to identify immunocompromised patients who, based on individual risk, are eligible to receive this tixagevimab with cilgavimab pre-exposure prophylaxis option. This option is not available to the general public at this time. If you are eligible, you will be contacted by a Nebraska Medicine case manager.

Supplies are very limited. It will not be possible for everyone who qualifies to receive this treatment at this time. 

Read more about tixagevimab with cilgavimab

Inpatient treatments

Remdesivir and dexamethasone are currently offered to some hospitalized COVID-19 patients.

  • Remdesivir is an anti-viral drug that slows the infection inside the body
  • Dexamethasone is a steroid that reduces inflammation caused by the virus

Learn more about remdesivir and dexamethasone at

Related Links:

Have questions? We're here to help.

Call for more information